SITES and Mach Medical New Manufacturing Headquarters Opens in Columbia City, Indiana

January 26, 2021

SITES and Mach Medical’s new advanced manufacturing headquarters recently opened in Columbia City, Ind., and began production of its orthopedic medical devices, which are the company’s signature products as the No. 2 life sciences producer in the United States.

The news was announced by Designed Collaborative, an award-winning, national Top 100 A/E architectural, engineering, and interior design firm located in downtown Fort Wayne, Indiana

Designed with an emphasis on innovation, collaboration, and efficiency within supply chain delivery, the new facility houses “state-of-the-art, high velocity, single piece flow manufacturing technology” capable of reducing inventory on-hand by 83 percent and the reducing the cost of goods by 48 percent, according to SITES Medical and Mach Medical’s estimates.
The new 36,000-square-foot facility enables cross-collaboration between the parent and sister entities, blurring the lines between office and manufacturing with a focus on connectivity in a modern industrial environment. With a recent acquisition behind them, a great opportunity presented itself for both entities to connect in a new location that supported a culture of innovation and collaboration in a space that encourages learning, adaptability, and growth with their teams over time.
Clean and simple were the drivers behind the modern aesthetic, which included a palette of natural tones and materials suitable for a clean manufacturing environment, as well as warm hues, wood ceilings, and bright fabrics and wallcoverings that create a welcoming office environment and nice compliment to the industrial space.
“We are excited for the future of SITES Medical and Mach Medical, as they cement their future as one of the top and most innovative providers in the life sciences devices space,” stated Lauren Elliott, RID, NCIDQ, IIDA, senior associate and workplace market leader.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version